Health Canada Approves BMS' Yervoy for Melanoma


Health Canada approved Yervoy (ipilimumab 3mg/kg, Bristol-Myers Squibb) for the treatment of unresectable or metastatic melanoma in patients who have failed or do not tolerate other systemic therapy for advanced disease. Yervoy was approved by the FDA for US marketing last year. According to submission data, the Kaplan-Meier estimated survival rate with Yervoy at both one and two years was almost doubled when measured against patients treated with gp100 peptide vaccine: 46 percent versus 25 percent at one year and 24 percent versus 14 percent at two years. Yervoy also showed long-term survival with some patients alive at three and four years. Read more about Yervoy in Practical Dermatology:

Facebook Comments


We’re glad to see you’re enjoying PracticalDermatology…
but how about a more personalized experience?

Register for free